Significant increase. It was announced that the start of the phase 1b trial and dose escalation part for the next-generation BTK inhibitor AS-1763, which is being developed for hematologic malignancies, has been decided and well received. In the interim results of the dose escalation part up to the present, it has been confirmed that AS-1763 has high safety and tolerability, sufficient plasma drug concentration that can be expected to produce therapeutic effects, and a high overall response rate. Therefore, under the agreement of the clinical trial principal investigator, it was decided to transition to the dose escalation part without waiting for the start of the maximum planned dose (600mg BID) in the dose escalation part.
カルナバイオ---大幅続伸、BTK阻害剤AS-1763のフェーズ1b試験・用量拡大パート開始決定
CarnaBio---Significant increase, Phase 1b trial and dose expansion part start decision of BTK inhibitor AS-1763.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.